CU20120086A7 - NEW AGOMELATINE CO-CRYSTALS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Google Patents

NEW AGOMELATINE CO-CRYSTALS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Info

Publication number
CU20120086A7
CU20120086A7 CU2012000086A CU20120086A CU20120086A7 CU 20120086 A7 CU20120086 A7 CU 20120086A7 CU 2012000086 A CU2012000086 A CU 2012000086A CU 20120086 A CU20120086 A CU 20120086A CU 20120086 A7 CU20120086 A7 CU 20120086A7
Authority
CU
Cuba
Prior art keywords
crystals
pharmaceutical compositions
compositions containing
preparation procedure
agomelatine
Prior art date
Application number
CU2012000086A
Other languages
Spanish (es)
Inventor
Philippe Letellier
Michael Lynch
Jean-Manuel Pean
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of CU20120086A7 publication Critical patent/CU20120086A7/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Nuevo co-cristal de agomelatina constituido: - por agomelatina o N-[2-(7-metoxi-1-naftil)etil]acetamida de fórmula (I) y - por un ácido orgánico MedicamentosNew agomelatine co-crystal consisting of: - by agomelatine or N- [2- (7-methoxy-1-naphthyl) ethyl] acetamide of formula (I) and - by an organic acid Medicines

CU2012000086A 2011-06-09 2012-05-31 NEW AGOMELATINE CO-CRYSTALS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CU20120086A7 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1101766A FR2976284B1 (en) 2011-06-09 2011-06-09 NOVEL CO-CRYSTALS OF AGOMELATIN, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Publications (1)

Publication Number Publication Date
CU20120086A7 true CU20120086A7 (en) 2014-01-29

Family

ID=46690337

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000086A CU20120086A7 (en) 2011-06-09 2012-05-31 NEW AGOMELATINE CO-CRYSTALS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Country Status (6)

Country Link
CN (1) CN102816079B (en)
AP (1) AP3198A (en)
CU (1) CU20120086A7 (en)
FR (1) FR2976284B1 (en)
HK (1) HK1178881A1 (en)
UA (1) UA112407C2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2810647A1 (en) * 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
EP2810656B1 (en) * 2013-06-06 2017-08-02 Zentiva, a.s. Agomelatine formulations comprising agomelatine in the form of co-crystals
PL3075724T3 (en) * 2015-03-31 2023-12-27 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Solid form of agomelatine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE457089B (en) * 1986-02-05 1988-11-28 Sandvik Ab PROVIDED TO TREAT A MIXTURE OF CARBON METAL BODIES TO Separate THESE FROM EACH OTHER ON THE BASIS OF THEIR COMPOSITIONS AND / OR STRUCTURES
FR2866335B1 (en) * 2004-02-13 2006-05-26 Servier Lab NEW PROCESS FOR THE SYNTHESIS OF AGOMELATIN
AP2009004960A0 (en) * 2007-02-27 2009-08-31 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same

Also Published As

Publication number Publication date
UA112407C2 (en) 2016-09-12
AP2012006308A0 (en) 2012-06-30
HK1178881A1 (en) 2013-09-19
CN102816079A (en) 2012-12-12
FR2976284A1 (en) 2012-12-14
AP3198A (en) 2015-03-31
FR2976284B1 (en) 2013-05-24
CN102816079B (en) 2015-04-08

Similar Documents

Publication Publication Date Title
CO6580196A1 (en) New agomelatine co-crystals, their preparation procedure and the pharmaceutical compositions containing them
BR112013017988A2 (en) bace-2 inhibitors for the treatment of metabolic disorders
ECSP13012770A (en) CRYSTAL FORMS OF 5-CHLORINE-N2- (2-ISOPROPOXI-5-METHYL-4-PIPERIDIN-4-IL-PHENYL) -N4- [2- (PROPAN-2-SULPHONYL) -PENYL] -PIRIMIDIN-2,4 -DIAMINE
CU20140081A7 (en) NEW DERIVATIVES OF PIRROL, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR112013031794A2 (en) oxytomodulin derivatives and pharmaceutical composition for the treatment of obesity comprising the same
ECSP12012249A (en) DERIVATIVES OF THE ACID 1-AMINO-2-CICLOPROPILETILBORONICO
SV2008003088A (en) NEW CRYSTAL FORM VI OF AGOMELATINE, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
UA110642C2 (en) Composition of herbicide and safeneru
ECSP16093323A (en) N- (CYANomethyl) -4- (2- (4-MORPHOLINOPHENYLAMINE) PYRIMIDIN-4-IL) BENZAMIDE
BR112014011254A2 (en) 2-thiopyrimidinones
PE20151979A1 (en) CHEMICAL COMPOUNDS
CL2015000976A1 (en) Compounds of 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine for use in the treatment of diabetes and its associated disorders.
CY1111287T1 (en) USE OF AGOMELATIN FOR TAKING MEDICINES INTENDED FOR TREATMENT OF GENERAL ANXIETY DISORDER
CL2015000879A1 (en) Derivatives of n- (2- (cyclic amine) ethyl) benzamide as p2x7 inhibitors.
BR112015001135A2 (en) histone deacetylase inhibitors and compositions and methods of use thereof
CL2012000013A1 (en) Compounds derived from 4- {3- [3- (4-trifluoromethyl-phenyl) ureido] -5-fluoro-benzylamino} -1h-pyrazole-3-carboxamide; preparation procedure; pharmaceutical composition comprising them; intermediate compounds; and their use as modulators of protein kinase activity for the treatment of cancer.
CU20120086A7 (en) NEW AGOMELATINE CO-CRYSTALS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR112014009760A2 (en) sialic acid analogs, their use and pharmaceutical composition and sustained release pharmaceutical composition comprising them
CY1120009T1 (en) USE OF AGOMELATIN FOR TAKING MEDICINES INTENDED FOR THE IDEO-PSYCHOGRAPHIC DISORDER TREATMENT (TOC)
CO7151504A2 (en) Metabolites of (1r-trans) -n - [[2- (2,3-dihydro-4-benzofuranyl) cyclopropyl] methyl] propanamide
ES2403549R1 (en) Agomelatine co-crystals with co-crystal formers
EA200702318A1 (en) APPLICATION OF AGOMELATIN TO OBTAIN MEDICINAL PRODUCTS INTENDED FOR THE TREATMENT OF THE SMITH-MAGENIS SYNDROME
EA201400365A1 (en) NEW THYRODUCT LACTS AS HIGHLY ACTIVE HDAC INHIBITORS AND THEIR APPLICATION AS MEDICINES
CR20120109A (en) NEW DIHIDRO-OXAZOLOBENZODIAZEPINONAS DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY33862A (en) New benzamide compounds, agrochemical compositions containing them, preparation processes and uses?